Table 3.

Overview of demographic and clinical information collected

Basics	Sample size	997
	Patients consented	531
	Number of variables	21
	Involvement in clinical trial	Yes, No
Demographics	Age
	Gender	Male, Female
	Ethnicity
	Inclusion in Clinical Trial	Yes, No
	Comorbidities	Hypertension, Diabetes, Other cancer, Hypercholesterolaemia, Respiratory disease, Cardiovascular disease, Chronic Kidney Disease, Psychiatric Disorder
	Smoking	Yes, No, Unknown
Bladder cancer characteristics	Diagnosis	New, Recurrent
	Histology	Urothelial Cell Carcinoma, Papillary Urothelial Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Micropapillary variant, Plasmacytoid variant, Paraganglioma, Papilloma, Small cell carcinoma, Sarcomatoid, Unknown
	Grade	G1, G2, G3
	TNM stage
	Lymphovascular invasion	Yes, No
	TURBT	Yes, No
	Surgery	Cystoprostatectomy, Cystectomy, Nephrouretectomy, Uretectomy, Nephrouretectomy and cystoprostatectomy, Cystectomy and ureterectomy, Diverticulectomy, Nephrouretectomy and cystectomy, Nephrouretectomy and partial cystectomy, Ureterostomy, Urethrectomy, Exenteration, None
	Chemotherapy	Neoadjuvant, Adjuvant, Chemotherapy, Palliative, Neoadjuvant and adjuvant, None
	Radiotherapy	Yes, No
	Intravesical therapy	Di Stasi, BCG, Mitomycin, BCG and mitomycin in different occasions, Di Stasi and mitomycin in different occasions, Other, None
	Intravesical therapy failure	Yes, No
	Laser ablation	Yes, No
	Immunotherapy	Yes, Poorly tolerated, Unknown, No, Not Applicable